trial

Indicated Prevention of Psychotic Disorders With Low-dose Lithium

NCTId NCT00202306
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 30 (estimated)
Sponsored by Melbourne Health
Primary completion 2006-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
30 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2001-11
Primary completion
2006-12
Eligibility
ALL · 15 Years · 30 Years

Interventions & indications

Drugs
lithium carbonate

Sponsors

Melbourne HealthLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Gregor E Berger, MDPrincipal Investigator

Sites

1 total
Parkville, Australia

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE4
Primary Completion Date
2006-12
Status
COMPLETED
relationships
The graph out of here
drug
lithium carbonate
drug
lead_sponsor
Melbourne Health
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Bipolar Disorder
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
investigator
Gregor E Berger, MD
person